Versartis, Inc. (VSAR)

[naturalborninvestor]

There are several more options, including resubmission at a higher dosage or buying revenues in an adjacent field. But a merger or acquisition is the most likely outcome. The drug certainly has value. Insiders had not put up in excess of $2 million through open market purchases if they expected this to just go out of business.